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A synthetic peptide, AAPAAAPAKQEAAAPAPAAKAEAPAAAPAAKA, proved to be an efficient and specific immu- 
nogen in rabbits. The amino acid sequence of the peptide is identical to that of the inter-domain region (PEP3) linking 
the innermost of the three lipoyl domains to the dihydrolipoamide hydrogenase-binding domain in the dihydrolipo- 
amide acetyltransferase chain of the pyruvate dehydrogenase complex of Escherichia coll. Fab fragments from anti-PEP3 
antibodies selectively inhibited active-site coupling in the complex without affecting the individual activities of the three 
component enzymes, highlighting the role of the inter-domain regions as flexible linkers in catalysis. 
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1. INTRODUCTION 
The pyruvate dehydrogenase (PDH) complex of 
Escherichia coli comprises an octahedrai (24-sub- 
unit) core of dihydrolipoamide acetyltransferase 
(E2p, EC 2.3.2.12) polypeptide chains to which are 
bound multiple copies of the pyruvate decarboxy- 
lase (Elp, EC 1.2.4.1) and dihydrolipoamide 
dehydrogenase (E3, EC !.8.1.4) subunits (review 
[1]). The N-terminal half of the E2p chain contains 
a succession of three highly homologous lipoyl do- 
mains each of about 80 amino acids [2,3]; these are 
linked to each other and then to a smaller (approx. 
50-residue) domain responsible, at least in part, for 
binding the E3 subunits [4,5]. The inter-domain 
segments (PEP1-3) of the polypeptide chain are 
long (20-30-residue) sequences rich in alanine, pro- 
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line and charged amino acids [2,3]. The E3-binding 
domain is in turn linked by a shorter and less con- 
spicuously (alanine+proline)-rich segment o a 
large (approx. 29 kDa) C-terminal, inner-core do- 
main that houses the acetyltransferase ctive site 
and binds the Elp and other E2p chains [4-6]. 
Movement of the lipoyl domains plays an impor- 
tant part in the mechanism of active-site coupling 
in the complex [7-9]. IH-NMR spectroscopy of the 
wild-type [10,11] and genetically engineered [6,12] 
PDH complexes and of appropriate synthetic pep- 
tides [13] has indicated that the (alanine + proline)- 
rich inter-domain segments of the E2p chains are 
indeed conformationally f exible. Two lipoyl do- 
mains can be deleted from the N-terminal end of 
the E2p chain without significant loss of catalytic 
activity in the resulting (pGSll0-encoded) PDH 
complex [14]. However, the creation of a set of 
nested eletions in the (alanine + proline)-rich seg- 
ment (PEP3) linking the single remaining lipoyl do- 
main to the E3-binding domains in the pGSll0- 
encoded E2p chain has revealed that this linker 
must be more than 13 residues long if it is to be ful- 
ly effective in active-site coupling [15]. 
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We show here that a 32-residue synthetic peptide 
whose amino acid sequence is identical to that of 
PEP3 is an efficient and specific immunogen in 
rabbits. Fab fragments derived from antibodies 
directed against his inter-domain sequence do not 
inhibit  the individual component  enzymes, but 
their b inding impairs the acetylation of lipoyl do- 
mains either by E lp  directly or by intramolecular 
transacetylat ion reactions between neighbouring 
lipoyl domains within the E2p core. These results 
highlight he role of the inter-domain segments of 
the E2p chain in catalysis. 
2. MATERIALS  AND METHODS 
2.1. Reagents and enzymes 
Papain, phosphotransacetylase and rabbit IgG were obtained 
from Sigma. Peroxidase-conjugated goat anti-rabbit IgG was 
purchased from Toyo (Burlingame, USA). Sodium [2-14C]py - 
ruvate was a product of Amersham International. All other 
reagents were of analytical grade. PDH complexes were pre- 
pared from wild-type E. coli KI2 [16] and from a suitable dele- 
tion strain of E. coli transformed with plasmids pGS110 [14], 
pGSl56 [17] or pGS186-188 [15]. PDH complex activity, Elp 
and E3 partial activities and the acetyltransferase ctivity of the 
E2p component were measured as described [3,18]. 
2.2. Preparation of antibodies and Fab fragments 
A peptide (Y-PEP3) with the sequence YAAPAAAPAK- 
QEAAAPAPAAKAEAPAAAPAAKA was synthesized bythe 
solid-phase method [19]. This sequence is identical to that of the 
innermost long (alanine + proline)-rich region (PEP3) of the 
E2p chain, except for the additional tyrosine residue at the N- 
terminus. The tyrosine residue was used to link the peptide to 
bovine serum albumin and the conjugate used to immunize rab- 
bits [20]. The IgG component was purified from the crude an- 
tiserum by ammonium sulphate precipitation followed by ion- 
exchange chromatography [21]. To prepare anti-PEP3 Fab 
fragments, IgG (20 mg/ml in 10 mM sodium phosphate buffer, 
pH 7.3, containing 15 mM NaC1, 2 mM EDTA and 10 mM cys- 
teine) was incubated with papain (10/0, w/v) for 3 h at 37°C and 
then dialysed against 10 mM sodium acetate buffer, pH 5.5, at 
4°C. The insoluble (Fc) and soluble (Fab) fragments were 
separated by centrifugation at 12000 x g for 15 rain at 4°C. 
Purification of the Fab fragments was completed by ion- 
exchange chromatography ona CM-cellulose column, using a 
linear gradient of 10 mM-1 M sodium acetate, pH 5.5 [22]. The 
Fab-containing fractions were pooled and dialysed vs 10 mM 
ammonium bicarbonate, pH 7.3, and lyophilized. 
2.3. SDS-polyacrylamide gelelectrophoresis and 
immunoblotting 
SDS-polyacrylamide gelelectrophoresis was carried out in 
15070 polyacrylamide slab gels and protein bands were visualised 
by staining with Coomassie brilliant blue followed by silver [3]. 
Proteins were transferred electrophoretically from SDS- 
polyacrylamide g ls onto nitrocellulose filters [23,24] and im- 
munoblots were developed by the method of Hawkes et al. [25] 
as modified by Johnson et al. [26]. 
2.4. Reductive acetylation of the PDH complex and 
active-site coupling 
Samples of the complex [25/zg, 1 mg/ml in 20 mM sodium 
phosphate buffer (pH 7.0), containing 1.5 mM NAD + and 
0.02% (w/v) NaNa] were progressively inhibited by the addition 
of increasing amounts (10-40/zml) of the Fab fragments (8 
mg/ml in 10 mM sodium phosphate buffer, pH 7.0). After 30 
min at room temperature, a portion (2/~g) was withdrawn and 
the overall complex activity assayed. To each sample thiamin 
pyrophosphate (TPP) and MgCI2 were added to give final con- 
centrations of 0.2 and 1.0 mM, respectively, and the mixture 
was incubated at 37°C for 2 rain. Sodium [2-14C]pyruvate (1-3 
/~l of 23 mM, 13.1 mCi/mmol) was then added, and the extent 
of acetylation ofthe E2p core after 45 s measured as in [18]. A 
control experiment was performed by replacing the Fab 
fragments with equivalent amounts of non-specific rabbit IgG. 
2.5. Crosslinking the PDH complex with N,N'-o-phenylene 
bismaleimide 
The pGS110-encoded complex (30/zg, 1.2 mg/ml in 20 mM 
sodium phosphate buffer, pH 7.0, containing 1.5 mM NAD ÷, 
0.2 mM TPP and 1 mM MgC12) was reductively acetylated and 
crosslinked with o-phenylene bismaleimide [27]. A further sam- 
ple of the complex (30/~g, 5mg/ml in the same buffer) was also 
reductively acetylated asabove. This sample was then incubated 
for 30 rain at room temperature with the anti-PEP3 Fab 
fragments (18/zl, 15 mg/ml in 20 mM sodium phosphate buffer, 
pH 7.0, final enzyme concentration 1.2 mg/ml), after which the 
overall complex activity was assayed and found to have fallen to 
less than 5% of its initial value. The sample was then treated 
with o-phenylene bismaleimide [27]. A control experiment was 
performed by replacing the anti-PEP3 Fab fragments with Fab 
fragments from non-specific rabbit IgG. 
3. RESULTS 
3.1. Specificity o f  anti-PEP3 antibodies 
The specificity of the ant i -PEP3 antibodies was 
investigated by immunoblot t ing (fig.l). Only the 
E2p subunits of wild-type and pGSl l0 -encoded 
PDH complexes were recognised by the antibodies, 
Little staining of any of the subunits was observed 
with the pre- immune serum (not shown). 
To define more precisely the epitope(s) in the 
E2p subunits, immunoblots  of the pGS156-, 186-, 
187- and 188-encoded complexes were also 
prepared. These complexes carry a nested set of 
deletions in the PEP3 segment of their E2p chains 
[15,17]. Significantly, the antibodies failed to 
recognise the pGS186-, 187- and 188-encoded E2p 
chains (the weak staining of these bands probably 
arises from non-specific binding), indicating that 
they are highly specific for their epitopes (fig.l). 
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Fig.1. Specificity of anti-PEP3 antibodies. The wild-type, 
pGSII0-, 156-, 186-, 187- and 188-encoded complexes were 
resolved by SDS-polyacrylamide gelelectrophoresis, blotted on- 
to nitrocellulose filters and overlaid with antibodies raised 
against he whole complex (panel I) or anti-PEP3 antibodies 
(panel II). a, wild-type; b, pGS110-; c, pGSI56-; d, pGS186-; e, 
pGS187-; f, pGS188-encoded complexes. 
Fig.2. Effect of anti-PEP3 Fab fragments on the activity of the 
pGSll0-encoded complex. (e) Overall complex activity; (O) 
Elp activity; (A) E2p activity; (A) E3 activity; and (,,) overall 
complex activity of control sample treated with equivalent 
amounts of non-specific rabbit IgG. Enzyme activities are ex- 
pressed as a percentage of those of the uninhibited sample. 
Since the deletions in the pGS156- and pGS186-, 
187- and 188-encoded E2p chains encompass 
residues 2-13, 2-20, 2-26 and 2-32, respectively, of
PEP3 [15,17], it is probable that one at least of the 
principal epitopes must lie between residues 13 and 
20 of PEP3, i.e., between residues 295 and 301 [15] 
of the wild-type E2p chain. 
3.2. Effect of antibody binding on catalysis and 
active-site coupling 
To study the effect of antibody binding on the 
PDH complex, Fab fragments were used to avoid 
any crosslinking of the E2p chains by the bivalent 
IgG molecule. Initial experiments with the wild- 
type complex indicated that it was inhibited by in- 
creasing amounts of Fab fragments but that some 
30070 of the activity remained unaffected. The 
simpler pGSll0-encoded complex was therefore 
employed for further experiments, ince it retains 
the region PEP3 but has only one lipoyl domain 
per E2p chain. Samples of the pGSll0-encoded 
PDH complex (25 gg, 0.5 mg/ml in 10 mM sodium 
phosphate, pH 7.0) were incubated for 30 min at 
room temperature with increasing amounts (0-25 
/A) of the anti-PEP3 Fab fragments (16 mg/ml in 
the same buffer). This caused progressive and 
almost complete loss of the overall complex activi- 
ty without effect on the activities of the three com- 
ponent enzymes (fig.2). 
The effect of the antibodies on the intramole- 
cular coupling of active sites [18,28,29] was there- 
fore investigated in more detail. As the PDH com- 
plex was inhibited by the addition of increasing 
amounts of anti-PEP3 Fab fragments, the extent 
of acetylation of the E2p core with [2-14C]pyruvate 
in the absence of CoA fell in direct proportion to 
the loss of overall complex activity (fig.3). In the 
PDH complex there normally exists a network of 
intramolecular transacetylation reactions, enabling 
acetyl groups to be passed between eighbouring 
lipoyl domains [28,29]. The results indicate there- 
fore that binding of the anti-PEP3 Fab fragments 
to the long (alanine + proline)-rich segments of 
the E2p chains inhibited direct reductive ace- 
tylation of the lipoyl domains by E lp and isolated 
them from the network of transacetylation reac- 
tions. As a control, the addition of non-specific 
rabbit IgG was found to have no effect either on 
the overall complex activity or on the acetylation 
curves (not shown). Acetylation of the uninhibited 
complex or of a complex inhibited to about 50°70 of 
the initial enzyme activity by treatment with the 
anti-PEP3 Fab fragments was shown to be com- 
plete within the 45 s incubation period with sodium 
[2-14C]pyruvate (not shown). 
3.3. Crosslinking of lipoyl domains 
The lipoyl moieties of adjacent E2p chains in the 
wild-type E. coil PDH complex can be crosslinked 
with o-phenylene bismaleimide after reductive 
acetylation with pyruvate [27,29]. Since the 
pGSll0-encoded E2p chain contains only one 
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Fig.3. Reductive acetylation of the pGS 110-encoded complex in 
the presence of anti-PEP3 Fab fragments. The overall complex 
activity and the proportion of E2p chains acetylated with 
sodium [2-14C]pyruvate are expressed as a percentage of the 
values for the uninhibited sample. 
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Fig.4. Crosslinking the pGS 110-encoded complex with N,N'-o- 
phenylene bismaleimide in the presence of anti-PEP3 Fab 
fragments. The pGSll0-encoded complex and complexes 
treated with non-specific or specific Fab fragments were expos- 
ed to o-phenylene bismaleimide in the presence of pyruvate. The 
products of crosslinking were examined by SDS-polyacrylamide 
gel electrophoresis, and the gel was stained with Coomassie blue 
followed by silver [3,27]. a, pGS110-encoded complex; b, com- 
plex treated with o-phenylene bismaleimide. Lanes c-e, 
pGS110-encoded complex inhibited with Fab fragments: c, star- 
ting material; d, sample following reductive acetylation and in- 
hibition with Fab fragments; e as d, but complex subsequently 
treated with o-phenylene bismaieimide. Lanes f-h, as lanes c-e, 
but samples incubated with non-specific Fab fragments which 
did not recognise or inhibit the complex. 
lipoyl domain, yet is fully active [14], it was ex- 
pected that crosslinking in this complex would 
generate only E2p dimers. The pGSll0-encoded 
complex and a complex crosslinked after exposure 
to non-specific Fab fragments yielded the expected 
E2p dimers (fig.4). However, prior binding of the 
anti-PEP3 Fab fragments to the pGSll0-encoded 
complex prevented imer formation. 
4. DISCUSSION 
In terms of the widely-studied problem of raising 
antibodies against synthetic peptides [30], it is 
noteworthy that peptide PEP3 was highly effective 
as an immunogen i  rabbits. The specificity for the 
antigen, the long (alanine + proline)-rich region 
linking the innermost lipoyl domain to the E3- 
binding domain in the E. coli E2p chain, was clear- 
ly demonstrated (fig.l), and one at least of the 
principal epitopes appears to reside between 
residues 295 and 301. 
The effect of the anti-PEP3 Fab fragments on 
the pGSll0-encoded PDH complex was clear-cut 
and specific: inhibition of active-site coupling 
(fig.3) and lipoyl domain juxtaposition (fig.4) 
without effect on the part-reactions of the in- 
dividual components (fig.2). This can be attributed 
to inhibition of the movements of the lipoyl do- 
mains caused by the Fab fragments binding to the 
segments of polypeptide chain linking the lipoyl 
domains to the bulk of the complex. The failure of 
the Fab fragments completely to inhibit the wild- 
type complex may be due to the additional two 
lipoyl domains per E2p chain being able still to par- 
ticipate in the reaction owing to residual flexibility 
in the segments of polypeptide chain linking these 
domains. 
On the basis of their susceptibility olimited pro- 
teolysis [1,3,31] and their identification as the 
origin of many of the unexpectedly sharp signals 
detected by 1H-NMR spectroscopy [10-13], the 
long (alanine + proline)-rich segments of the E. 
coli E2p chain are thought o be exposed to solvent 
and conformationally flexible. Perhaps it is not so 
surprising, therefore, that peptide PEP3 is strongly 
immunogenic and that the anti-PEP3 Fab frag- 
ments can bind effectively to the PDH complex. 
The lipoyl domains protrude from the inner E2p 
core, interdigitating between the Elp and E3 sub- 
units (review [1]); the binding of the Fab fragments 
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can therefore be envisaged as the insertion of 
wedges into hinge regions of the E2p chains, 
limiting the movement of the lipoyl domains and 
disrupting their participation in the system of 
active-site coupling. 
The outermost two long (alanine + proline)- 
rich segments of the E. coli E2p chain resemble in 
many ways the innermost one (PEP3) studied here. 
It will be interesting to see how these regions 
behave as immunogens and how this correlates 
with their conformations a studied by NMR spec- 
troscopy and other biophysical techniques [13]. 
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